Boardroom Alpha
Boardroom Alpha
PMI · Additional Proxy Materials (DEFA14A) · Filed July 8, 2026

Picard Medical Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
July 8, 2026
Ticker
PMI
Accession
0001437749-26-022976
Boardroom Alpha · Filing insights

Picard Medical issues a proxy supplement correcting the advisory vote frequency to 1/2/3 years and updating Audit Committee disclosures.

About Picard Medical Inc
Market cap
$12M
1Y TSR
−98.3%
Board grade
D
Sector
Healthcare
CEO
Richard Fang
Last annual meeting: Jul 17, 2026 · View full Picard Medical Inc profile →
pmi20260707_defa14a.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 14A

(Rule 14a-101) 

 

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

 

 

 

Filed by the Registrant

 

Filed by a Party other than the Registrant ☐

 

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) 

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material under §240.14a-12 

 

 

 

logo.jpg

 

Picard Medical, Inc.

(Name of Registrant as Specified in its Charter)

 

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

No fee required

 

Fee paid previously with preliminary materials

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 

 

 

 

EXPLANATORY NOTE

 

This supplement (the “Proxy Supplement”) updates the Definitive Proxy Statement, dated June 26, 2026 (collectively, the “Proxy Statement”), previously furnished to stockholders of Picard Medical, Inc., a Delaware corporation (the “Company”), in connection with its 2026 Annual Meeting of Stockholders to be held on July 17, 2026 at 3:00 p.m. Mountain Time (the “Annual Meeting”).

 

This Proxy Supplement is being filed to (i) correct an administrative oversight on the proxy card that previously was furnished to stockholders and (ii) correct the disclosure describing the membership of the Audit Committee of the Company. 

 

Specifically, Proposal Three of the proxy card regarding the advisory vote on the frequency of future advisory votes on the compensation of our named executive officers incorrectly gave stockholders the option to vote “For,”” Against” or “Abstain” a frequency of one year, rather than giving stockholders to vote for “1 year,” “2 years” or “3 years.” Accordingly, the Company is providing a revised proxy card to its stockholders as of the record date for the Annual Meeting to provide the voting options “1 year,” “2 years” or “3 years.” Any votes previously cast “FOR” the proposal will be counted as a vote for “1 year.”

 

In addition, the disclosure under the caption "The Board, Its Committees and its Compensation- Audit Committee" is amended and restated in its entirety as follows:

 

Audit Committee

 

Sam Van and George Ye serve as members of our audit committee, with Sam Van serving as the chair of the Audit Committee. The Board has determined that each member of the audit committee satisfies the independence requirements under the NYSE Listing Rules and Rule 10A-3(b)(1) of the Exchange Act. Sam Van, the chair of the audit committee, is an “audit committee financial expert” within the meaning of SEC regulations. Each member of the audit committee is able to read and understand fundamental financial statements in accordance with applicable listing standards. In arriving at these determinations, we examine each audit committee member’s scope of experience and the nature of his or her employment. The primary purpose of the audit committee is to discharge the responsibilities of the Board with respect to corporate accounting and financial reporting processes, systems of internal control, and financial statement audits, and to oversee our independent registered public accounting firm. The audit committee met 1 time during the fiscal year ended December 31, 2025. Specific responsibilities of the audit committee include:

 

helping the Board oversee the corporate accounting and financial reporting processes;

 

managing and/or assessing the selection, engagement, qualifications, independence, and performance of a qualified firm to serve as the independent registered public accounting firm to audit our consolidated financial statements;

 

discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end operating results;

 

developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters;

 

reviewing related party transactions;

 

reviewing our policies on risk assessment and risk management;

 

reviewing, with the independent registered public accounting firm, our internal quality control procedures, any material issues with such procedures and any steps taken to deal with such issues; and

 

pre-approving audit and permissible non-audit services to be performed by the independent registered public accounting firm.

 

Our audit committee operates under a written charter, that satisfies the applicable NYSE Listing Rules.

 

If you are a stockholder of record, you may change your vote or revoke your proxy at any time before it is voted at the Annual Meeting by:

 

delivering a written notice of revocation of your proxy to the attention of the Corporate Secretary at the following address: 1992 E Silverlake, Tucson AZ, 85713;

 

delivering to us an authorized proxy bearing a later date (including a proxy over the Internet or by telephone); or

 

attending the virtual Annual Meeting and voting during the meeting. Attendance at the Annual Meeting will not, by itself, revoke a proxy.

 

If your shares are held in the name of a bank, broker or other nominee, you may change your vote by submitting new voting instructions to your bank, broker or other nominee, or as otherwise instructed by such bank, broker or nominee.

 

Except as described herein, this Proxy Supplement does not modify, amend, supplement, or otherwise affect the Proxy Statement.

 

 

picardproxy_01.jpg
 

picardproxy_02.jpg
 
From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Picard Medical Inc (PMI)

Reference

Frequently asked questions

When did Picard Medical Inc file this DEFA14A?
Picard Medical Inc (PMI) filed this Additional Proxy Materials (DEFA14A) with the SEC on July 8, 2026. The accession number assigned by EDGAR is 0001437749-26-022976.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Picard Medical issues a proxy supplement correcting the advisory vote frequency to 1/2/3 years and updating Audit Committee disclosures. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Picard Medical Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Picard Medical Inc has filed under CIK 2030617, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer